

Antithymocyte globulin use for treatment of biopsy confirmed acute rejection is associated with prolonged renal allograft survival

A. Kainz, R. Korbély, A. Soleiman, B. Mayer, R. Oberbauer


Table of contents

| | |
|---|----|
| Table of contents | 1 |
| Evaluation with missing data | 2 |
| Variables used in propensity score model..... | 3 |
| Confounders which change hazard ratio more than 10 percent | 4 |
| Schoenfeld residuals..... | 6 |
| Functional graft survival | 6 |
| Actual graft survival..... | 10 |
| Patient survival..... | 14 |
| Analyses with first transplantation only | 18 |
| Functional graft survival | 18 |
| Actual graft survival..... | 19 |
| Patient survival..... | 20 |
| Summary | 21 |
| Analyses with first transplantation and BCAR in first three months..... | 22 |
| Functional graft survival | 22 |
| Actual graft survival..... | 23 |
| Patient survival..... | 24 |
| Summary | 25 |

Evaluation with missing data

Webfigure 1 shows that the hazard ratio for OKT3 vs ATG usage and 95 % confidence intervals are nearly the same, when missing data are replaced by the median of the respective group.

Red lines indicated with “m” in the model name represent the models computed with data missing, black lines (without indication in model name) represent the hazard ratio and 95 % confidence interval when missing data are replaced.



Variables used in propensity score model

Webtable 1 lists the variables which are used in the logistic regression for computing the propensity score of ATG use.

| Variable | Type of variable | Meaning of variable |
|---------------------|------------------|--|
| obs_n_DiabetesID_1 | binary | Diabetes Type 1 |
| obs_n_diabetesid_2 | binary | Diabetes Type 2 |
| obs_vascid1 | binary | cerebrovascular disease |
| obs_vascid2 | binary | periphervascular disease |
| obs_khk | binary | cardiovascular disease |
| obs_cmp | binary | heart insufficiency and other heart disease |
| obs_pu1a | binary | proteinuria 500 – 3500 mg/d |
| obs_pu2a | binary | proteinuria >3500 mg/d |
| obs_MAP | continuous | mean arterial pressure |
| obs_bloodpressidneu | discret | number of antihypertensive drugs |
| obs_n0_oraleDM | binary | oral antidiabetics |
| obs_n0_Insulin | binary | insulin |
| obs_ImmId1 | discret | Immunsuppression ID: steroid + AZA + CsA steroid + MMF + CsA steroid free else |
| obs_DonorAge | continuous | donor age |
| obs_PRA | continuous | panel reactive antibody |
| obs_DGF | binary | delayed graft function |
| obs_can | binary | chronic allograft nephropathy |
| obs_cholest | continuous | laboratory (annually) cholesterin |
| obs_hb | continuous | laboratory (annually) haemoglobin |
| obs_gfr | continuous | calculated glomerular filtration rate (MDRD) |
| obs_mmsum | discrete | HLA mismatch sum |
| obs_banffmax | discrete | Banff score |

For variables which were missing the value of the “miss-“ variable were set to 1

| | | |
|--------------|------------|---|
| miss_vascid1 | binary | |
| miss_khk | binary | |
| miss_pu1a | binary | |
| miss_MAP | binary | |
| miss_DGF | binary | |
| miss_cholest | binary | |
| miss_hb | binary | |
| miss_gfr | binary | |
| rawscore_adj | continuous | Score computed from the time weighted pattern of missing values |

Confounders which change hazard ratio more than 10 percent

Webtables 2a to 2c list the modification of hazard ratio for OKT3 vs. ATG usage in the automated model, which is calculated as a bivariable model.

Webtable 2a

Functional graft survival

| Confounder | Modification of crude HR (%) | Modification of adjusted HR (%) |
|---------------------------|-------------------------------------|--|
| donorage | -6.1461 | . |
| Banff | 3.6465 | . |
| HLA mismatch sum | 0.2055 | . |
| PRA | -2.3206 | . |
| Number of transplantation | 1.5947 | . |
| Year of transplantation | 19.6485 | -19.6485 |

Webtable 2b

Actual graft survival

| Confounder | Modification of crude HR (%) | Modification of adjusted HR (%) |
|---------------------------|-------------------------------------|--|
| donorage | -4.3402 | . |
| Banff | 1.7480 | . |
| HLA mismatch sum | -0.0240 | . |
| PRA | -1.6355 | . |
| Number of transplantation | 0.1328 | . |
| Year of transplantation | 17.6827 | -17.6827 |

Webtable 2c
Patient survival

| Confounder | Modification of crude HR (%) | Modification of adjusted HR (%) |
|------------------------------|---|--|
| donorage | -2.5159 | . |
| Banff | -0.3497 | . |
| HLA mismatch sum | -0.0459 | . |
| PRA | 0.4267 | . |
| Number of transplantation | -0.7300 | . |
| Year of transplantation | 21.6072 | -21.6072 |

Schoenfeld residuals

Functional graft survival


Webtable 3

Correlation matrix of the variables with followup time and rank of followup time.


| Pearson Correlation Coefficients, N = 136 Prob > r under H0: Rho=0 | | |
|---|----------------|------------------------|
| | Follow-up time | Rank of follow-up time |
| ATG | 0.05003 | 0.05373 |
| | 0.5630 | 0.5344 |
| donorage | 0.04384 | 0.04590 |
| | 0.6123 | 0.5957 |
| Banff score | 0.05047 | 0.04863 |
| | 0.5595 | 0.5740 |
| HLA mismatch sum | 0.05382 | 0.02978 |
| | 0.5337 | 0.7308 |
| PRA | 0.00264 | 0.04445 |
| | 0.9756 | 0.6073 |
| Number of transplantation | -0.07689 | -0.10996 |
| | 0.3736 | 0.2025 |
| Year of transplantation | 0.05003 | 0.05373 |
| | 0.5630 | 0.5344 |

Webfigure 2a


Schoenfeld residuals of OKT vs. ATG use




Webfigure 2b
Schoenfeld residuals of donorage




Webfigure 2c
Schoenfeld residuals of Banff score




Webfigure 2d
Schoenfeld residuals of HLA mismatch sum




Webfigure 2e
Schoenfeld residuals of PRA



Webfigure 2f
Schoenfeld residuals of number of transplantation



Webfigure 2g
Schoenfeld residuals of year of transplantation



Actual graft survival


Webtable 4

Correlation matrix of the variables with followup time and rank of followup time.


| Pearson Correlation Coefficients, N = 184 Prob > r under H0: Rho=0 | | |
|---|--------------------|------------------------|
| | Follow-up time | Rank of follow-up time |
| ATG | 0.07797 0.2928 | 0.10686 0.1488 |
| donorage | -0.09451 0.2019 | -0.09283 0.2101 |
| Banff score | -0.26228 0.0003 | -0.31098 <.0001 |
| HLA mismatch sum | -0.00175 0.9812 | 0.00021 0.9977 |
| PRA | 0.05353 0.4705 | 0.03429 0.6440 |
| Number of transplantation | -0.00406 0.9564 | 0.02405 0.7459 |
| Year of transplantation | -0.01500 0.8399 | -0.02944 0.6915 |

Webfigure 3a


Schoenfeld residuals of OKT vs. ATG use




Webfigure 3b
Schoenfeld residuals of donorage




Webfigure 3c
Schoenfeld residuals of Banff score




Webfigure 3d
Schoenfeld residuals of HLA mismatch sum




Webfigure 3e
Schoenfeld residuals of PRA



Webfigure 3f
Schoenfeld residuals of number of transplantation



Webfigure 3g
Schoenfeld residuals of year of transplantation



Patient survival


Webtable 5

Correlation matrix of the variables with followup time and rank of followup time.


| Pearson Correlation Coefficients, N = 105 Prob > r under H0: Rho=0 | | |
|---|--------------------|------------------------|
| | Follow-up time | Rank of follow-up time |
| ATG | 0.05311 0.5905 | 0.06081 0.5377 |
| donorage | -0.27636 0.0043 | -0.26935 0.0055 |
| Banff score | -0.06406 0.5162 | -0.06196 0.5301 |
| HLA mismatch sum | -0.04134 0.6755 | -0.06268 0.5253 |
| PRA | 0.08202 0.4055 | 0.08109 0.4109 |
| Number of transplantation | 0.03926 0.6909 | 0.03824 0.6985 |
| Year of transplantation | -0.04159 0.6735 | -0.03711 0.7070 |

Webfigure 4a


Schoenfeld residuals of OKT vs. ATG use




Webfigure 4b
Schoenfeld residuals of donorage




Webfigure 4c
Schoenfeld residuals of Banff score




Webfigure 4d
Schoenfeld residuals of HLA mismatch sum




Webfigure 4e
Schoenfeld residuals of PRA



Webfigure 4f
Schoenfeld residuals of number of transplantation



Webfigure 4g
Schoenfeld residuals of year of transplantation



Analyses with first transplantation only

The following analyses include only patients who experienced a BCAR during the first renal allograft.

Functional graft survival

Webtable 6

Associations between OKT3 use and functional graft loss using different model-building strategies

| Parameter | Hazard Ratio | 95 % confidence interval | | p-value |
|-------------------------------|--------------|--------------------------|------|---------|
| <i>Propensity score model</i> | | | | |
| OKT3 vs. ATG usage | 1.56 | 0.84 | 2.88 | 0.157 |
| <i>Automated model</i> | | | | |
| OKT3 vs. ATG usage | 1.28 | 0.69 | 2.35 | 0.434 |
| Year of transplantation | 0.88 | 0.82 | 0.95 | <0.001 |
| <i>Clinical expertise</i> | | | | |
| OKT3 vs. ATG usage | 1.33 | 0.71 | 2.48 | 0.370 |
| Donor age | 1.01 | 1.00 | 1.03 | 0.084 |
| BANFF 2 vs. 1 | 1.26 | 0.84 | 1.90 | 0.263 |
| BANFF 3 vs. 1 | 3.48 | 1.74 | 6.93 | <0.001 |
| HLA mismatch | 0.99 | 0.83 | 1.18 | 0.949 |
| PRA | 1.01 | 0.99 | 1.02 | 0.565 |
| Year of transplantation | 0.87 | 0.80 | 0.94 | <0.001 |

Actual graft survival

Webtable 7

Associations between OKT3 use and actual graft loss using different model-building strategies

| Parameter | Hazard Ratio | 95 % confidence interval | | p-value |
|-------------------------------|---------------------|---------------------------------|------|----------------|
| <i>Propensity score model</i> | | | | |
| OKT3 vs. ATG usage | 1.55 | 0.91 | 2.63 | 0.110 |
| <i>Automated model</i> | | | | |
| OKT3 vs. ATG usage | 1.27 | 0.75 | 2.15 | 0.382 |
| Year of transplantation | 0.90 | 0.84 | 0.95 | <0.001 |
| <i>Clinical expertise</i> | | | | |
| OKT3 vs. ATG usage | 1.35 | 0.79 | 2.31 | 0.277 |
| Donor age | 1.01 | 1.00 | 1.02 | 0.049 |
| BANFF 2 vs. 1 | 1.34 | 0.95 | 1.88 | 0.098 |
| BANFF 3 vs. 1 | 2.55 | 1.30 | 4.99 | 0.006 |
| HLA mismatch | 1.02 | 0.88 | 1.18 | 0.817 |
| PRA | 1.01 | 0.99 | 1.02 | 0.302 |
| Year of transplantation | 0.88 | 0.83 | 0.94 | <0.001 |

Patient survival

Webtable 8


Associations between OKT3 use and patient mortality using different model-building strategies

| Parameter | Hazard Ratio | 95 % confidence interval | | p-value |
|-------------------------------|--------------|--------------------------|-------|---------|
| <i>Propensity score model</i> | | | | |
| OKT3 vs. ATG usage | 1.39 | 0.71 | 2.73 | 0.342 |
| <i>Automated model</i> | | | | |
| OKT3 vs. ATG usage | 1.09 | 0.56 | 2.12 | 0.805 |
| Year of transplantation | 0.87 | 0.81 | 0.95 | <0.001 |
| <i>Clinical expertise</i> | | | | |
| OKT3 vs. ATG usage | 0.95 | 0.23 | 3.98 | 0.944 |
| Donor age | 1.02 | 1.00 | 1.04 | 0.073 |
| BANFF 2 vs. 1 | 1.59 | 0.86 | 2.94 | 0.139 |
| BANFF 3 vs. 1 | 2.67 | 0.61 | 11.73 | 0.195 |
| HLA mismatch | 1.09 | 0.84 | 1.42 | 0.509 |
| PRA | 0.97 | 0.90 | 1.05 | 0.480 |
| Year of transplantation | 0.76 | 0.68 | 0.85 | <0.001 |

Summary

Webfigure 5

Forest plot of hazard ratios for OKT3 use as shown in the webtables 6 - 8. The hazard ratios remained virtually unchanged compared to the overall analyses that included also retransplanted subjects. As expected, due to a lower number of patients and thus outcomes, the 95% CI are wider.



Analyses with first transplantation and BCAR in first three months

The following analyses include only patients who experienced a BCAR during the first three months after implantation of the first renal allograft.

Functional graft survival

Webtable 9

Associations between OKT3 use and functional graft loss using different model-building strategies

| Parameter | Hazard Ratio | 95 % confidence interval | | p-value |
|-------------------------------|--------------|--------------------------|------|---------|
| <i>Propensity score model</i> | | | | |
| OKT3 vs. ATG usage | 1.61 | 0.80 | 3.25 | 0.182 |
| <i>Automated model</i> | | | | |
| OKT3 vs. ATG usage | 1.39 | 0.69 | 2.78 | 0.358 |
| Year of transplantation | 0.91 | 0.83 | 0.99 | 0.029 |
| <i>Clinical expertise</i> | | | | |
| OKT3 vs. ATG usage | 1.51 | 0.84 | 2.72 | 0.344 |
| Donor age | 1.01 | 1.00 | 1.03 | 0.050 |
| BANFF 2 vs. 1 | 1.29 | 0.89 | 1.87 | 0.482 |
| BANFF 3 vs. 1 | 2.63 | 1.33 | 5.20 | <0.001 |
| HLA mismatch | 1.02 | 0.86 | 1.19 | 0.997 |
| PRA | 1.01 | 1.00 | 1.03 | 0.165 |
| Year of transplantation | 0.90 | 0.83 | 0.99 | 0.029 |

Actual graft survival

Webtable 10

Associations between OKT3 use and actual graft loss using different model-building strategies

| Parameter | Hazard Ratio | 95 % confidence interval | | p-value |
|-------------------------------|---------------------|---------------------------------|------|----------------|
| <i>Propensity score model</i> | | | | |
| OKT3 vs. ATG usage | 1.73 | 0.96 | 3.11 | 0.068 |
| <i>Automated model</i> | | | | |
| OKT3 vs. ATG usage | 1.43 | 0.80 | 2.56 | 0.225 |
| Year of transplantation | 0.92 | 0.86 | 0.99 | 0.020 |
| <i>Clinical expertise</i> | | | | |
| OKT3 vs. ATG usage | 1.51 | 0.84 | 2.72 | 0.173 |
| Donor age | 1.01 | 1.00 | 1.03 | 0.027 |
| BANFF 2 vs. 1 | 1.29 | 0.89 | 1.87 | 0.179 |
| BANFF 3 vs. 1 | 2.63 | 1.33 | 5.20 | 0.006 |
| HLA mismatch | 1.02 | 0.86 | 1.19 | 0.848 |
| PRA | 1.01 | 1.00 | 1.03 | 0.116 |
| Year of transplantation | 0.91 | 0.84 | 0.98 | 0.013 |

Patient survival

Webtable 11

Associations between OKT3 use and patient mortality using different model-building strategies

| Parameter | Hazard Ratio | 95 % confidence interval | | p-value |
|-------------------------------|--------------|--------------------------|-------|---------|
| <i>Propensity score model</i> | | | | |
| OKT3 vs. ATG usage | 1.81 | 0.85 | 3.87 | 0.122 |
| <i>Automated model</i> | | | | |
| OKT3 vs. ATG usage | 1.42 | 0.67 | 3.01 | 0.359 |
| Donor age | 1.02 | 1.01 | 1.04 | 0.010 |
| Year of transplantation | 0.88 | 0.80 | 0.97 | 0.008 |
| <i>Clinical expertise</i> | | | | |
| OKT3 vs. ATG usage | 1.06 | 0.25 | 4.57 | 0.937 |
| Donor age | 1.03 | 1.00 | 1.05 | 0.034 |
| BANFF 2 vs. 1 | 1.67 | 0.85 | 3.27 | 0.136 |
| BANFF 3 vs. 1 | 2.86 | 0.64 | 12.78 | 0.170 |
| HLA mismatch | 1.09 | 0.82 | 1.44 | 0.546 |
| PRA | 0.98 | 0.86 | 1.12 | 0.787 |
| Year of transplantation | 0.77 | 0.66 | 0.90 | <0.001 |

Summary

Webfigure 6

Forest plot of hazard ratios for OKT3 use as shown in the webtables 9 - 11. The hazard ratios remained virtually unchanged compared to the overall analyses that included also retransplanted subjects, as well as the analysis with first allografts only but BCAR at any time after transplantation.

